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Retrotransposons like L1 are silenced in somatic cells by a variety of mechanisms acting at diﬀerent levels. Protective mechanisms
includeDNAmethylationandpackagingintoinactivechromatintosuppresstranscriptionandpreventrecombination,potentially
supported by cytidine deaminase editing of RNA. Furthermore, DNA strand breaks arising during attempted retrotranspositions
ought to activate cellular checkpoints, and L1 activation outside immunoprivileged sites may elicit immune responses. A number
of observations indicate that L1 sequences nevertheless become reactivated in human cancer. Prominently, methylation of L1
sequences is diminished in many cancer types and full-length L1 RNAs become detectable, although strong expression is restricted
to germ cell cancers. L1 elements have been found to be enriched at sites of illegitimate recombination in many cancers. In theory,
lack of L1 repression in cancer might cause transcriptional deregulation, insertional mutations, DNA breaks, and an increased
frequency of recombinations, contributing to genome disorganization, expression changes, and chromosomal instability. There
is however little evidence that such eﬀects occur at a gross scale in human cancers. Rather, as a rule, L1 repression is only partly
alleviated. Unfortunately, many techniques commonly used to investigate genetic and epigenetic alterations in cancer cells are
not well suited to detect subtle eﬀects elicited by partial reactivation of retroelements like L1 which are present as abundant, but
heterogeneouscopies.Therefore,eﬀectsofL1sequencesexertedonthelocalchromatinstructure,onthetranscriptionalregulation
of individual genes, and on chromosome fragility need to be more closely investigated in normal and cancer cells.
Copyright © 2006 Wolfgang A. Schulz.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
In normal somatic human cells, transcription of retrotrans-
poson sequences like L1 and illegitimate recombination in-
volving them are suppressed, restricting their activity to de-
veloping germ cells and placental tissues [1–3]. Suppression
ofretroelementactivitypreventsnotonlyretrotransposition,
but also various disturbances of transcription by retroele-
ment promoters, interference by retroelement enhancers,
the activity of retroelement-encoded enzymes, and illegiti-
mate recombination between homologous elements. More-
over, whileL1 sequenceshave the potential tocreategenomic
instability,theyprobablyexertcertainbeneﬁcial,“symbiotic”
eﬀects.Forinstance,silencingofretrotransposons insomatic
cells may help to organize the genome into macro- and mi-
crodomains with diﬀerential transcriptional activity. Failure
to silence retroelements in cancer cells could therefore per-
m i ta d v e r s ea c t i v i t i e so fr e t r o e l e m e n t sa sw e l la sp e r t u r ba n y
beneﬁcial eﬀects.
The present paper summarizes current knowledge about
L1(LINE-1)retrotransposonsinhumancancer.Forcompar-
ison, some observations on human endogenous retroviruses
(HERV) are included [4]. Throughout the text, the emphasis
will be on identifying open questions, of which there are
plenty, as should become evident.
Since L1 general biology is treated in detail in recent
reviews [1–3] and other contributions in this issue, only a
short introduction will follow here. L1 sequences represent
the major class of LTR-less retrotransposons in humans and
constitute about 18% of the human genome. While they
are interspersed throughout the genome, including euchro-
matic and heterochromatic regions, they are particularly fre-
quent in gene-poor regions that correspond to chromoso-
mal G-bands. Full-length elements are 6kb in size and con-
tain an internal promoter at the 5 -end that generates a ge-
nomic transcript which also serves as an mRNA. The RNA
contains two open reading frames, ORF1 and ORF2. ORF1
encodes p40, an RNA-binding protein with cis preference
for L1 RNA. ORF2 encodes the endonuclease and reverse
transcriptase required for retrotransposition. Only a frac-
tion of L1 elements in the human genome are intact. Most
are truncated, usually at the 5 -end, and mutated, often at
many sites. The up to 400,000 elements that are still dis-
tinctly recognizable as L1 can be categorized into several
subclasses. Most and perhaps all elements still capable of
retrotransposition belong to a subclass named Ta. Normally,2 Journal of Biomedicine and Biotechnology
transcriptional activity of L1 is restricted to developing germ
cells and to cells of the placenta. In somatic cells, L1 tran-
scription and retrotransposition is prevented by a variety
of control mechanisms, including methylation of L1 DNA
and speciﬁcally L1 promoters. In the germline, these mech-
anisms are relaxed, and retrotransposition does occur occa-
sionally.
Potentialdangers
Dangers resulting from L1 reactivation in cancer cells com-
prise the direct adverse eﬀects of retrotransposition, en-
hanced illegitimate recombination, and multiple ways of dis-
turbance of transcriptional activity and gene regulation. In
the human genome, fewer than 100 L1 elements are thought
to be suﬃciently intact for retrotransposition [3]. However,
while the danger of retrotransposition is posed only by these
intact L1s, other adverse eﬀects can be exerted by a larger
number of elements. In addition, reactivation may interfere
with potential “symbiotic” eﬀects of L1 sequences such as
their contribution to the global and local organization of
the genome and the provision of gene regulatory sequences.
Activities on the immune system can also be envisioned.
These would be expected to have ambiguous consequences.
It seems therefore imprecise to consider alterations of L1 in
cancersolely as “reactivation,” other eﬀectsmay more appro-
priately be characterized as “dysregulation.”
Retrotransposition
The mechanisms involved in L1 retrotransposition are now
q u i t ew e l lu n d e r s t o o d[ 1–3]. The endonuclease encoded by
L1 ORF2 induces single-strand breaks at AT-rich DNA tar-
get regions, preferably at consensus TTTT/A sites. Following
L1 ORF2 endonuclease action, the L1 RNA poly-A sequence
pairswitholigo-dTsequencesinthetargetDNA,whichserve
as primers for reverse transcription by the L1 ORF2 encoded
enzyme. Reverse transcription yields a branched DNA struc-
ture, which is presumably resolved by cellular DNA repair
systems. The retrotransposition mechanism thus requires at
least one recombination and creates two DNA single-strand
breaks close to each other, which can in eﬀect behave like
a double-strand break. Therefore, attempted or successful
retrotranspositions carry a high risk of eliciting chromo-
some breaks, deletions, translocations, and recombinations
[5]. Moreover, successful retrotransposition events are likely
to change the activity of genes at the insertion site. Di-
verse outcomes of insertions are conceivable, including in-
creased or decreased transcriptional activity and the gener-
ation of novel, variant transcripts (Figure 1). On a genome-
wide scale, the eﬀects of retrotranspositions might be mit-
igated by the propensity of L1 elements to insert into AT-
rich, gene-poor regions of the genome, and especially into
or close to other elements [6]. However, even retrotransposi-
tions outside transcriptional units can have catastrophic ef-
fects on a cell by inducing DNA strand breaks and initiating
a breakage-fusion-bridge cycles [7].
Effectsontranscription
T h e o r e t i c a l l y ,aw i d er a n g eo fe ﬀects on the transcription
of host genes can be exerted by L1 regulatory elements and
transcriptional sequences that are located close to or within
them(Figure 1).TheL1promoterismoderatelystrong[8,9]
and the polyadenylation signal is relatively weak permit-
ting a substantial amount of read-through [10, 11]. There-
fore, active L1 promoters located in sense orientation 5  to a
gene could override the normal transcriptional controls of a
gene to deregulate expression. Active L1 promoters located
in sense orientation within the transcriptional unit could
generate alternative 5 -truncated transcripts. Indeed, many
regulatory elements of human genes are derived from L1 or
HERV sequences [12]. Even some protein-coding sequences
arederivedfromretroelements.Aprominentexampleissyn-
cytin1, a crucial protein required for the formation of syn-
cytic cells in the placenta which has evolved from an HERV
env protein [13]. The gene encoding syncytin1 is now conse-
quently named ERVWE1 for “endogenous retrovirus W en-
velope protein1.” As in this case, regulatory sequences de-
rived from L1 or HERV sequences are often more active dur-
ing germ cell or embryonic development than in somatic
cells. In cancer cells, decreased methylation and a more open
chromatin structure of such sequences could therefore allow
the reexpression of genes or transcripts that are normally
restricted to germ cells or the embryo, that is, oncofetal or
cancer-testis gene expression.
Alternative transcripts may also be generated by the use
ofpolyadenylationsitesofintragenicL1sequences,especially
if these are 5 -truncated. As mentioned above, L1 polyadeny-
lation signals are weak. It is not known which mechanism
ensures that they are normally ignored in elements located
within a transcriptional unit. Consequently, it is diﬃcult to
estimatehowalteredmethylationandchromatinstructurein
cancer cells would aﬀect their recognition.
Retroelements oriented in opposite direction inside a
transcriptional unit might interfere with transcription by
antisense eﬀects, most prominently through formation of
dsRNA. This mechanism is implicated in the generation of
heterochromatin in some organisms [14, 15]. In mammalian
cells, dsRNA ought to induce general cellular antiviral de-
fense mechanisms, for example, by activating PKR, or leads
to the production of siRNAs and gene-speciﬁc downregula-
tion. Interestingly, transcripts containing Alu sequences in
sense direction appear to be edited and consequently desta-
bilized in human cells [16–18]. This mechanism provides
an obvious means of posttranscriptional gene regulation. It
is possible that a similar process acts on L1 sequences, but
it is currently unknown to what extent intact or partial L1
sequences in pre-mRNA are edited and whether such se-
quences are employed for posttranscriptional gene regula-
tion, in normal or in cancer cells. A recent study [19] sug-
gests that L1 RNAs are not edited, at least not by the usual
APOBEC3G cytidine deaminase.
Afurtherpossibilityhasbeensuggestedbytherecentdis-
covery of an antisense promoter near the 5 -end of intact
L1 sequences [20]. When active, this promoter could exertWolfgang A. Schulz 3
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Figure 1: Potential eﬀects of L1 sequences on transcriptional regulation. (a) schematic view of a human gene. One L1 element is located
upstream of the gene and one within. Panels (b)–(g) show various disturbances that could be caused by partial or complete reactivation
of L1 elements: (b) deregulation by upstream L1 promoter; (c) transcriptional interference by the promoter of an L1 in inverse direction
to the gene; (d) generation of an alternative 5 -truncated transcript by an internal L1 promoter in sense direction; (e) generation of an
alternative 5 -truncated transcript by the antisense promoter of an internal L1 element in inverse direction to the gene; (f) transcriptional
interference by the antisense promoter of an internal L1 element oriented in sense direction; (g) generation of a truncated transcript by use
of the poly-adenylation site of an internal L1 element. Note that most eﬀects do not require intact retrotransposons.
several eﬀects on cellular genes, depending on its orienta-
tion. If located in sense direction, antisense transcripts could
lead to downregulation; if located in antisense direction, it
might lead to overexpression of normal transcripts or the
emergence of novel transcripts. Accordingly, demethylation
of L1 sequences in cancer cells may not only activate their
canonical sense, but also their antisense promoters [21].
EffectsofL1-encodedproteins
Intact L1 elements contain two open reading frames. ORF1
encodes a p40 RNA-binding protein supposed to act as a
chaperone and transport factor for L1 RNA. ORF2 encodes
an endonuclease and a reverse transcriptase. The properties
of these enzymes have meanwhile been studied quite well in
vitro[22–24],buttheirimpactonnormalandcancercellsre-
mains diﬃcult to estimate. One open question is how many
L1elementsareactuallycapableofexpressingactiveproteins,
especially, whether only intact elements form the source. It is
thought that less than 100 L1 sequences are capable of retro-
transposition whichallbelong totheTafamily[25].Theyare
the most likely source of reverse transcriptase, endonuclease,
and p40 protein in germ cells and the embryo as well as in
cancer cells. However, many elements of other families are
also intact, except for missense and stop mutations. They
could still give rise to one or the other intact protein, as
wellasvariantproteins.Aluretrotranspositionusestheenzy-
matic machinery provided by L1 and is therefore dependent
on expression of L1 proteins [26, 27]. Similarly, complemen-
tation of transposition in trans among L1 sequences is inef-
ﬁcient, but not impossible [28], that is, full-length L1s with
mutated protein-coding sequences might still be capable of
retrotransposition, if proteins are supplemented by other el-
ements. The proteins provided by L1s are also most likely in-
volved in the formationof pseudogenes. It is unknown, how-
ever, whether their endogenous expression levels in cancer
cells are suﬃcient to support retrotransposition.
Importantly, the potential danger of proteins encoded by
L1s depends critically on their ability to exert eﬀects beyond
aiding retrotransposition in cis or in trans. In the context of4 Journal of Biomedicine and Biotechnology
cancer, dangers posed by the endonuclease are most obvious.
The endonuclease introduces single-strand breaks “(nicks)”
into DNA with moderately stringent speciﬁcity [23]. Its ac-
tivity is further restricted by chromatin structure [22]. The
ultimate result of single-strand breaks introduced by the en-
donuclease in a cell depends on several factors. A ﬁrst factor
isthecellcyclephase.Nicks inS-phasearemostproblematic,
because they can be converted into double-strand breaks by
the replication complex. DNA repair competence and capac-
ity constitute a second factor that may diﬀer between normal
and cancer cells. Thirdly, the presence of L1 RNA and other
proteins at the nicked site would be thought to inﬂuence the
type and eﬃciency of repair.
The potential impact of L1 reverse transcriptase and
RNA-binding protein similarly depend on their speciﬁcity,
actually in two respects. First, to which extent are they spe-
ciﬁc for L1 (and Alu) sequences? Second, are reverse tran-
scription and RNA-chaperoning their sole activities? Drug
inhibitors of reverse transcriptase and, more speciﬁcally,
siRNA directed against L1 RT decrease the proliferation of
cancer cell lines [29]. Such eﬀects are diﬃcult to explain by
the known function of the enzyme in mediating L1 and Alu
retrotranspositions.
Illegitimaterecombination
Successful and abortive retrotransposition can create chro-
mosomal instability and initiate illegitimate recombina-
tion by inducing DNA strand breaks and by generating
a branched DNA structure. However, even in the absence
of retrotransposition, the presence of thousands of intact,
rather long (6kb), and relatively homologous sequences in
the genome plus the presence of ten thousands of truncated
and mutated sequences carries a permanent risk of illegit-
imate recombination between elements located at diﬀerent
sites. In the germline, recombination between diﬀerent L1
elements contributes to human evolution, but also elicits in-
herited diseases. In somatic cells, recombination ought to
be restricted strictly to homologous recombination repair
of DNA double-strand breaks using homologous sequences
from sister chromatids or at most from the homologous
chromosome. Any other recombination event involves dele-
tions, insertions, or translocations. It is generally assumed
that recombination between L1 sequences in somatic cells
is suppressed by dense DNA methylation and tight pack-
aging into chromatin. Decreased methylation and relaxed
chromatin structure of L1 sequences in cancer cells might
therefore facilitate illegitimate recombination contributing
to chromosomal instability.
Disturbanceofnormalgenomeorganization
L1 sequences are thought to be involved in the organiza-
tion of the human genome, their presence inﬂuencing short-
rangeandlong-rangechromatinstructures.L1sequencesare
overrepresented in the late-replicating G-bands of human
chromosomes [30]. It is plausible that their presence is re-
sponsible for their more heterochromatic character. L1s are
also overrepresented on the X-chromosome [31] where they
may act as “way stations” during X-chromosome inactiva-
tion [32, 33]. In a similar fashion, methylated L1 sequences
on other chromosomes which are packaged into hyperme-
thylatedanddeacetylatedchromatinmayconstitutethecores
of localized facultative heterochromatic regions. A fraction
of centromeric heterochromatin also consists of retrotrans-
posons, mostly of L1s [34]. Intriguingly, some L1 sequences
are associated with nuclear matrix attachment regions [35]
and may contribute to the organization of chromatin loops.
L1 clusters located between genes may furthermore con-
tribute to the segmentation of the genome into transcrip-
tional units, helping to prevent interference by regulatory el-
ements from neighboring genes (Figure 2). Such a “bound-
ary” function would explain why HOX clusters, which re-
quirelong-rangeinteractionsfortheirproperexpressionpat-
tern, are largely devoid of retroelement sequences [30]. Im-
portantly, the organization of the genome into subregions
andloopspertainsnotonlytotranscription,butalsotorepli-
cation and imposes restrictions on the extent of DNA repair
and recombination.
Accordingly, alterations of DNA methylation and chro-
matin structure at L1 sequences in cancer cells could have
eﬀects not only on transcription, but also on DNA replica-
tion timing and on the extents of recombination and DNA
repair. Deregulation of gene expression could not only be
caused by activation of L1 elements, but also through altered
chromatin structure at inactive L1s allowing transcriptional
interference by neighboring enhancers or silencers. Not only
in this particular situation DNA replication patterns could
bedisturbed,withnormallylate-replicatingDNAshiftingto-
wards earlier periods within S-phase. Barrier functions of re-
peat DNA in the genome could be alleviated, allowing DNA
processing during repair and Holiday junctions formed dur-
ing recombination to pass through stretches of DNA that are
less accessible in normal cells [36].
Effectsoncellstressandimmuneresponses
Endogenous retroelements have been implicated in the reg-
ulation of cell stress responses, of the immune system, and
in the pathogenesis of several human autoimmune diseases.
The strongest data on regulation of human retroelements by
cell stress concern Alu sequences [37]. Likewise, the most
convincing data on regulation of the immune system by
retroelements and on the involvement in autoimmune dis-
eases implicates HERVs [4]. There are, however, indications
that L1 sequences too are induced during stress responses
[37], during cytotoxic chemotherapy [38] ,a n db yU Ve x p o -
sure of skin cells [39]. Furthermore, L1 sequences may act
in a similar fashion as HERVs in at least one autoimmune
disease, rheumatoid arthritis [40]. In this disease, synovial
ﬁbroblasts become aberrantly activated in a fashion that re-
sembles in many respects ﬁbroblast activation in the stroma
of malignant tumors, with enhanced proliferation, migra-
tion, and secretion of cytokines, chemokines, and proteases.
The ﬁbroblast genomes at large and L1 promoters in partic-
ular were found to become hypomethylated. Concurrently,
full-length L1 RNA could be detected [41]. OverexpressionWolfgang A. Schulz 5
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Figure 2: Postulated boundary eﬀect of intergenic L1 clusters. Being strongly methylated and tightly packed into chromatin, clustered L1
sequences might act as boundaries between genes, restricting the interaction of an enhancer (ENH) to one gene (a). In cancer cells, L1
hypomethylation could destroy this function and cause deregulation by allowing enhancer interaction with a neighboring gene (b).
of the p40 ORF1 protein in this disease has been suggested
to activate stress-induced protein kinases [42]. It is thought
that L1 hypomethylation and expression provide an ampli-
ﬁcation step in the pathogenesis of the disease by enhancing
immune responses [40].
The function of the activation of retroelements during
cellular stress responses is poorly understood. Conceivably,
it forms part of a signaling system that alerts the immune
system to the presence of infected or altered cells [43]. If that
proposition is true,hypomethylation and activationof L1se-
quences in cancer cells are likely to inﬂuence the immune re-
sponse to malignant tumors. In support of this idea, some
HERV proteins have been found to behave as tumor antigens
[44, 45], but it is not known whether proteins encoded by L1
do so too. A similarly open question is to which extent hy-
pomethylated repeat DNA liberated from tumor cells elicits
danger signals in cells regulating the immune response. In-
terestingly, L1 activation is considered as a cause of increased
plasma DNA levels in tumor patients [46].
Observations
Many of the eﬀects that can be envisioned to be exerted
by activated L1 retrotransposons have indeed been observed
in the human germline and during fetal development [1–
3, 47, 48]. In cancer cells, mainly three phenomena point
towards a reactivation of retroelements. Retroelement DNA
sequences become hypomethylated, transcripts as well as
protein products can be detected, and L1 sequences are lo-
cated at sites of breakage and recombination. For L1 retro-
transposons, the most convincing data are available for hy-
pomethylation. Data on L1 expression are scarce, in contrast
to several reports on the expression of HERV gene products.
L1 sequences have been found at or near deletion ends and
translocation breakpoints, but the precise frequency and the
mechanisms involved remain to be determined. Intriguingly,
actual retrotransposition events are exceptional.
Alteredmethylation
In a large number of human cancers, decreased methylation
of L1 sequences has been documented (Table 1). This de-
crease occurs in the context of general alterations in DNA
methylationpatternsthataccompanycarcinogenesisinmany
human tissues. These are regarded as part of an important
epigenetic mechanism driving cancer development and pro-
gression [63]. Alterations of methylation in cancer cells
comprise “hypermethylation” which occurs focally and in a
largely speciﬁc fashion, typically at CpG islands surrounding
the transcriptional start regions of individual genes. Some-
what paradoxically, in many, but not all cancers, increased
methylation at speciﬁc sites is found alongside a decrease
in methylation levels of the overall genome. The decrease in
methylation appears to be relatively unspeciﬁc and is there-
fore commonly designated as “genome-wide” or “global” hy-
pomethylation [64, 65]. In normal somatic cells, the bulk
of methylcytosine is found in repetitive sequences such as
L1, HERVs, and Alus, but also at CpG-rich satellites such as
SAT2 and SAT3. The overall decrease in methylation found
in cancer cells therefore reﬂects a largely parallel decrease in
themethylationofretrotransposonsequences[61].Asarule,
however, L1 and HERV sequences seem to be more strongly
aﬀected than Alus [65].
Hypomethylation of L1 sequences has traditionally been
investigated by Southern blot analysis following digestion of
DNA with methylation-sensitive restriction enzymes [53].
Recently, methods employing PCR following bisulﬁte treat-
ment of DNA have been developed for this purpose [52, 66].
These techniques are promising, since they can also be ap-
plied to small amounts of suboptimal quality DNA. How-
ever, because of the heterogeneity of L1 sequences, the extent
of their demethylation is diﬃcult to estimate precisely, espe-
cially by PCR-based methods. Southern blot analyses suggest
thatin cancercelllinesupto70%–80% ofCpGsitesinL1se-
quences become demethylated. Decreases in L1 methylation
appear to parallel those in HERVs. Accordingly, individual
HERV proviruses are essentially unmethylated in cancer cell
lines with strong hypomethylation [53]. Nevertheless, L1 hy-
pomethylation is anything but uniform in diﬀerent cancers,
in two respects. First, diﬀerent extents of hypomethylation
are found in cancers of the same type. These diﬀerences are
also observed in cancer cell lines and are therefore not ex-
plained by diﬀerences in the proportion of tumor cells in tis-
suesamples.Second,L1hypomethylationappearstodevelop
at diﬀerent stages in the development of diﬀerent cancers.
For instance, it is found at early stages of colon and blad-
der cancers [53, 60], but only in higher-stage prostate carci-
nomas [55, 56] while primary renal carcinomas lack signif-
icant LINE-1 hypomethylation [52, 53]. Germ cell cancers
are a special case since they have generally hypomethylated6 Journal of Biomedicine and Biotechnology
Table 1: Hypomethylation and expression of L1 in human cancers.
Change reported Cancer type Remarks References
Expression Teratocarcinoma Cell lines [49, 50]
Hypomethylation Various Cell lines [51]
Hypomethylation Various Cell lines [46]
Hypomethylation Many Considerable diﬀerences between cancer types [52]
Hypomethylation, expression Bladder cancer Expression weaker than in teratocarcinomas [53, 54]
Hypomethylation Renal carcinoma Cell lines only [53]
Hypomethylation Prostate cancer Increases with stage and metastasis [55–57]
Hypomethylation Liver carcinoma — [58]
Hypomethylation, expression Liver carcinoma Hypomethylation, but not cancer-speciﬁc expression [59]
Hypomethylation Various cancers Diﬀerences between cancer types [52]
Hypomethylation Colon cancer Begins in preneoplastic mucosa [60]
Hypomethylation Gastric cancer Correlates with overall hypomethylation [61]
Hypomethylation Ovarian carcinoma — [62]
genomes, presumably due to their origin from cells with
lower methylation levels [67, 68]. Accordingly, L1 [51, 69]
and HERV [70] sequences are strongly hypomethylated in
testicular cancers. Finally, note that very little is known on
the methylation of individual L1 sequences [71], and accord-
ingly, whether their hypomethylation in cancers is uniform
[72].
Although genome-wide hypomethylation in human can-
cers has been known for more than twenty years, the mech-
anisms eliciting this alteration are still unknown. Hypo-
thetical mechanisms include insuﬃcient levels of methyl
group donors, ultimately of S-adenosylmethionine, inade-
quate expression or regulation of DNA methyltransferases,
reexpression of DNA demethylases, and altered expression
of chromatin regulators directing DNA methyltransferases
[64, 65].
The last mechanism is particularly interesting in the
present context. Retroelements constitute approximately
45% of the human genome [30] and contain an at least pro-
portionateamountofmethylcytosine.Moreover,theyappear
to be preferentially recognized by the DNA methylation ma-
chinery and—at least in some circumstances—appear to act
as “centers of methylation” from which methylation spreads
into adjacent sequences [73]. Therefore, genome-wide hy-
pomethylation could theoretically arise as a consequence of
a defect in the recognition of retroelements as methylation
targets.
Unfortunately,itisstillnotknownhowretroelementsare
distinguished for silencing in mammalian genomes. The L1
promoter is as active in somatic as in embryonic cells [9].
Therefore, L1 silencing in somatic cells cannot be simply
a consequence of transcriptional inactivity. Instead, silenc-
ing must have been actively established during fetal devel-
opment and is faithfully maintained through cell prolifera-
tionanddiﬀerentiationinnormalsomaticcells.DNAmethy-
lation of retroelements is established ﬁrst during germ cell
development and then again during gastrulation, when the
genome at large becomes de novo methylated, except for
sequences that are actively protected, such as CpG islands
and active imprinted genes [74]. De novo methylation in
the mouse embryo requires DNA methyltransferases, specif-
ically Dnmt3A and Dnmt3B as well as Dnmt1 for mainte-
nance of the established methylation [74, 75]. In male germ
cells, Dnmt3L is required for proper L1 methylation [76]. It
is not entirely clear whether methylation of L1 during de-
velopment requires speciﬁc chromatin regulators directing
the methyltransferases. One candidate is SMARCA6, as its
mouse orthologue Lsh has been found to be required for
proper methylation of L1 sequences. Inactivation of Lsh in
mice causes L1 hypomethylation, but only limited distur-
bances of the methylation of single-copy genes [77]. In com-
parison, inactivation of another chromatin protein ATRX
causes hypomethylation of rDNA, but leaves L1 methylation
intact [78]. This suggests that the speciﬁcity of DNA methy-
lation may be regulated by speciﬁc “chromatin regulator”
proteins.
A variety of chromatin regulator proteins have been re-
ported to be aberrantly expressed or even mutated in human
cancers[65,79–81].However,manyofthesechangesarerare
or are speciﬁc to particular cancers. It is therefore diﬃcult to
envision a change in a single “master regulator” of L1 methy-
lation as the cause of the widely distributed hypomethylation
of these sequences. More likely, L1 hypomethylation could
be associated with the general reorganization of chromatin
structureinaneuploidcancercellsthatdisturbsthecompart-
mentation of the genome [65, 79, 80]. Genome-wide alter-
ations in histone modiﬁcation have recently been described
in cancer cells [82, 83]. Given the high proportion of L1
sequences in the human genome, these are likely to aﬀect
these retrotransposons and to interact with their methyla-
tion. Note that the relation between DNA methylation and
histone modiﬁcations at L1 sequences is far from being un-
derstood [84].
L1expressionincancers
The mechanisms underlying hypomethylation changes in
human cancers are not understood, but even the descriptionWolfgang A. Schulz 7
of these changes is fragmentary. For instance, methylation
of HERVs has been studied in only a few cancers. Avail-
able data suggest that they are aﬀected by genome-wide hy-
pomethylation in parallel to LINE-1 sequences (Table 1). In
selected cancers, endogenous retroviral sequences may be al-
most completely unmethylated. Expressed sequences derived
from HERVs are found in germ cell cancers and antibod-
ies directed against HERV-encoded proteins are found in the
blood of patients [70]. In cancers of somatic cell origin, bona
ﬁde transcripts for envelope and auxiliary proteins have been
reported, especially in breast cancer [44, 85], and recently
in melanoma [86]. Some results suggest that HERV expres-
sion occurs in a wider range of cancers and even normal
tissues [87, 88]. These data need further veriﬁcation to ex-
cludeartifactsfromgenomicDNAandunsplicedtranscripts.
Moreover, the somewhat surprising ﬁndings that diﬀerent
transcripts from diﬀerent subfamilies may be expressed in a
cancer-type-speciﬁc fashion call for a closer analysis of the
mechanisms involved.
There are no suﬃc i e n t l ys y s t e m a t i cs t u d i e so fL 1e x p r e s -
sion in human cancers. The available data suggest that ex-
pression of full-length L1 sequences is by far the strongest in
teratocarcinomas, while weaker expression is observed in a
wider range of carcinomas exhibiting hypomethylation [53].
This expression pattern therefore resembles that of HERVs.
Since HERVs also give rise to spliced transcripts, RNA anal-
yses can provide a ﬁrst indication of which protein products
are expressed. For L1, this question needs to be addressed us-
ing antibodies. So far, no deﬁnite data have been published
on the expression of the proteins encoded by the retrotrans-
posons in human cancer. Their presence in germ cell cancers
and teratocarcinoma cell lines, however, is very likely [89].
InvolvementofL1inchromosome
breakageandrecombination
Whereas retrotransposition events take place quite regularly
in the germline, at an estimated rate of 1 event per 100 births
[3, 4] ,v e r yf e wh a v eb e e nr e p o r t e di nc a n c e rc e l l s[ 90, 91].
Similarly,althoughL1sequenceshavebeenshowntobecome
incorporated at sites of double-strand break DNA repair in
model experiments [92], according sequence changes have
only exceptionally been observed in human cancers [93]. In
spite of the caveats discussed below, it is therefore probably
safeto conclude that actualretrotransposition events are rare
inhumancancersanddonotregularlycontributetogenomic
instability.
The evidence is better for indirect mechanisms by which
retrotransposons could promote chromosomal instability in
human cancer. L1 hypomethylation and chromosomal insta-
bility correlate well with each other in several cancer types
[55, 58, 94]. A similar relationship has been observed be-
tweenthehypomethylationoftandemsatellitesequencesand
alterations of the chromosomes that carry them as large jux-
tacentromeric region [95–97]. In this case, hypomethylation
of the satellite sequences is thought to cause decondensation
of pericentromeric chromatin and an increased propensity
for chromosomal breaks and rearrangements in this region.
In a similar fashion, hypomethylation of retroelement se-
quences dispersed in the genome could facilitate illegitimate
recombination. In favor of this idea, L1 sequences are en-
riched at the ends of 3p14.1 and 9p21 deletions in carcino-
mas [36, 98, 99] and homozygous deletions arise preferen-
tially in chromosomal regions with high LINE content [100].
It has also been suggested that L1 and HERV sequences are
involved in the formation of double-minute circular chro-
mosomes in cancer cells [101, 102].
The most straightforward hypothesis accounting for
these ﬁndings is that decreased methylation and presumably
more open chromatin structure at L1 sequences in cancer
cells favors the illegitimate recombination between elements
at diﬀerent genomic locations, for example, during homolo-
gous recombination repair of DNA strand breaks. However,
closer analyses of the deletion ends in solid tumors indi-
cate that this hypothesis is probably incorrect. While dele-
tion ends are indeed often located in or near L1 sequences
and particularly L1 clusters, the breakpoints invariably show
hallmarks of DNA double-strand break repair by nonhomol-
ogousend-joining(NHEJ).Typically,oneendofthedeletion
is located in or close to an L1 sequence, while the other end
is provided by an unrelated single copy or repeat sequence
[36, 99, 103]. Such structures also appeared as occasional
endproductsofrepairofDNAdouble-strandbreaksinduced
by a restriction endonuclease at a speciﬁc chromosomal site
[104]. A plausible explanation for this structure is that pro-
cessing by the NHE1 protein complex damaged DNA ends
is slowed down at L1 sequences by denser chromatin, favor-
ing reannealing and ligation there [36]. If this explanation is
correct, retroelement hypomethylation in cancer could para-
doxically diminish the tendency of breakpoints to be located
at L1 sequences. It would instead tend to increase the size
of deleted and recombinated sequences, because DNA pro-
cessing and Holiday junctions arising during recombination
repair could move further through more open chromatin.
Presently, either hypothesis remains speculative for sev-
eral reasons. First of all, far too few chromosomal break-
points have been investigated, especially in carcinomas. Sec-
ondly, it has not been established for any chromosomal al-
teration whether hypomethylation of repeat sequences at the
aﬀected site preceded it. Thirdly, L1 repeats are not randomly
distributed in the genome. They might be associated with lo-
cal structures that are particularly prone to breakage, such as
fragile sites or the anchorage sites of chromatin loops.
Perspectives
Consequences of L1 activity in the human germline are
well documented. Retrotranspositions in the germline take
place at a signiﬁcant rate of approximately 1 event per 100
births [3]. In addition, a substantial number of recombina-
tion events involving L1 elements have been detected, typi-
cally because they elicited translocations or rearrangements
causing inherited diseases [2, 47, 48]. Speciﬁcally, L1 retro-
transposition and illegitimate recombination in the germline
are causes of inherited and congenital cancers. For instance,
a germline deletion in the MLH1 gene carries hallmarks8 Journal of Biomedicine and Biotechnology
of recombination initiated by a failed L1 retrotransposition
event [105].
In contrast, in spite of considerable evidence hinting at
a reactivation of L1 retrotransposons in a variety of human
cancers, there is limiting evidence for major consequences of
this process. This may be due to two very diﬀerent reasons.
One is technical: even typical eﬀects expected from L1 reac-
tivation are diﬃcult to detect by the techniques commonly
used to investigate genetic alterations in human cancers. The
other is biological: reactivation may be partial and the mech-
anisms ensuring silencing of L1 DNA sequences and limiting
theeﬀectsoftranscribedsequencesmayremainfunctionalto
some degree. Perhaps, limited reactivation of L1 sequences
may exert eﬀects more through the loss of symbiotic func-
tionsthanthroughdirectadverseeﬀectsongenomicstability.
This possibility is even more diﬃcult to ascertain.
In general, investigations of genetic and epigenetic
changes in human cancers avoid dealing with repeat se-
quences and focus on single-copy protein-coding genes. Mu-
tation analysis of genes is typically restricted to coding se-
quences and employs PCR techniques to analyze individual
exons or mRNA. Insertions or recombinations caused by L1
or other retroelements would often not be detected by this
approach,unlesstheyoccurwithinexons.Therefore,itmight
not be coincidental that reports describing oncogene acti-
vation and tumor suppressor inactivation by L1 insertion
date from a period when Southern blot analysis was more
en vogue.
Similarly,recombinationanddeletionsincancersarewell
documented at the levelaccessibleby cytogenetic techniques,
but are not well investigated at the molecular level, with the
important exception of translocations in hematological can-
cers. In these, retroelements have indeed been found at many
translocation sites, although their role in the generation of
the translocations is not clear. In contrast, very few studies
have addressed the precise structure of chromosomal break-
points in solid tumors. A recent genome-wide study of 505
cancer cell lines yielded a strong association between LINE
content and the presence of homozygous deletions, but no
breakpointswerecharacterizedindetail[100].Detailedanal-
yses of deletion endpoints at the FRA3B fragile site [98]a n d
around CDKN2A at 9p21 [99] revealed a preponderance of
L1sequencesatorclosetothedeletionendpoints.Suchanal-
yses remain tedious even with the ﬁnished human genome
sequence having become available. Therefore, we know little
on the structure of amplicons, another category of unstable
sequence in cancer cells, and next to nothing on the sites of
illegitimate recombination in cancer cells. L1 sequences have
been detected in double minutes, an important intermediate
in one ampliﬁcation mechanism, and have been proposed,
but not proven to be involved in their formation [101]. By
a comparison of loss of heterozygosity analysis and cytoge-
netic techniques of chromosome 8p in bladder cancer cell
lines, recombination events were recently shown to be much
more frequent and were shown to take place across much
smaller regions than hitherto assumed [106]. However, it
is not known and diﬃcult to determine what initiated the
recombination events and which sequences precisely were
involved. In summary, therefore, whereas it seems unlikely
thatretrotranspositioniscommoninhumancancercells,the
role of L1s in recombination and chromosome breakage is
probably underestimated due to a lack of studies with appro-
priate methodology.
A similar argument can be made for epigenetic eﬀects of
L1 sequences in cancer. In genome-wide screens for altered
methylation in cancer, repeat sequences are often and un-
derstandably considered a nuisance and typically removed
by prehybridization. Overall changes in L1 methylation are
therefore well documented, but data on the behavior of indi-
vidual sequences is lacking. Bisulﬁte sequencing is restricted
to a few hundred bp per PCR and is prone to artifacts from
template switching and target priming when applied to re-
peat sequences. An elegant solution may be hairpin PCR.
This method has revealed that in fetal ﬁbroblasts, the pro-
motersofmostfull-lengthL1sequencesaredenselyandsym-
metrically methylated, while selected elements are unmethy-
lated [71]. The obvious question is which elements are these.
Accordingly,itisnotclearwhetherthenumberofcompletely
unmethylated elements increases in cancer cells or whether
the decrease in methylation is distributed across all L1 se-
quences. These questions extend of course to the issue of
chromatin structure at L1 elements.
ThecontributionofL1stoalteredgeneexpressionincan-
cer is still more diﬃcult to ascertain. There are many unex-
plained instances of altered gene expression in cancers. Per-
haps most striking are reports on frequent downregulation
of genes (usually tumor suppressor candidates) without de-
tectable genetic alterations in their vicinity and altered DNA
methylation in regulatory sequences. Recently, increased ex-
pression of miRNA has been introduced as a potential cause
of such enigmatic observations [107]. In the light of poten-
tial eﬀects of L1 sequences, perhaps eﬀects exerted by L1 el-
ements in or near aﬀected genes should also be considered.
This suggestion likewise applies the mechanisms generating
aberranttranscriptsincancercells[21].Again,thisisahighly
diﬃcult issue, especially if genes that are investigated are al-
ternatively spliced even in normal cells. The argument can
be broadened further to encompass the potential boundary
function of repeat elements. Its disturbance by altered chro-
matin structure in cancer cells may result in more or less
subtle up- and downregulation. More than two decades of
intense work have been spent on a small number of selected
loci to understand the mechanisms of action of long-range
regulatory elements and boundary elements at all. It is un-
derstandable that very little is known on how they are altered
in cancer cells. Still, it may be advisable to consider such ef-
fects and others mentioned in this paragraph when encoun-
tering instances of altered gene regulation in cancer that can-
not be straightforwardly explained by mutations or altered
DNA methylation of gene regulatory sequences.
The diﬃculties in determining the impact of L1 se-
quencesincancercellsresultingfrommethodologicallimita-
tions are compounded by biological factors. Several layers of
mechanisms control L1 expression and activity. DNA methy-
lation inactivates the L1 promoter [9]. It is likely that this
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chromatin structure [108], although this cannot be consid-
eredproven[86].AsecondsetofL1controlsappearstoactat
the RNA level, perhaps exerted by cytidine deaminases, lead-
ing to RNA instability [11]. Alu-containing RNAs are subject
to editing [16–18], but the evidence for L1 RNA is scanty.
A third level of control is enacted at the retrotransposition
step. Active TP53 prevents retrotransposition [109], but this
is very likely not the only barrier at this step. Last and per-
haps not least, there is some evidence that retroelement ac-
tivation might attract immune responses. As discussed else-
where in detail [43], such responses are better documented
for HERVs, but they might additionally or concurrently se-
lect against cells with strongly activated L1 retrotransposons
outside immunoprivileged organs.
There is good evidence for three of these protective
mechanismstobeimpededincancercells:DNAmethylation
is decreased, TP53 and checkpoints are often defective, and
immune responses to advanced cancers are muted. We know
very little about another mechanism, control of retroele-
ments at the RNA level. In summary, therefore, the regula-
tion of L1 genomic structure, expression, and retrotranspo-
sition is clearly perturbed in many human cancers, but inac-
tivation of all tiers of control may be rare. Some cancer types
exhibit fewchanges,forexample, renalcellcarcinoma,where
even L1 DNA methylation appears to be maintained, while
germ cell cancers appear to represent the other end of the
spectrum [49, 50, 52, 53]. Even in these, however, retrotrans-
position events appear to be rare and the evidence for major
contributions of retrotransposon activity to the cancer phe-
notype is limited. Presumably, at least one of the multiple
safeguards against retrotransposition holds up. A likely can-
didate is TP53 [109] ,s i n c eg e r mc e l lt u m o r sa r ea m o n gt h e
few cancer types in which mutations of this tumor suppres-
sor are rare [68].
CONCLUSIONS
Activation of L1 retrotransposons in cancer cells is expected
to exert a variety of eﬀects on the tumor phenotype, if it oc-
curs. Of course, this statement hinges on the “if,” and our
present knowledge does not allow ﬁrm conclusions. Consid-
ering that L1 retrotransposons make up almost a ﬁfth of our
genome, there are astonishingly large gaps in our knowledge
on their general biology, and consequentially in our knowl-
edge on their behavior in cancer. As argued above, there is
an obvious need for more systematic investigations of DNA
methylation and chromatin structure of L1 DNA, of the ex-
pression of full-length transcripts and L1-encoded proteins
on one hand and for exemplary studies of individual ele-
mentsandtheirinﬂuenceonadjacentgenesincancercellson
the other hand. At this stage, it is probably safe to conclude
that L1 retrotransposons do become reactivated to various
degrees in diﬀerent cancers, but that some of the many safe-
guards that prevent retrotransposition and their adverse ef-
f e c t si ns o m a t i cc e l l sh o l du pi nm o s tc a n c e r s .P e r h a p s ,e v e n
cancercellscannotsurvivewithfullyactiveretrotransposons.
It follows that more subtle eﬀects of L1 dysregulation in can-
cer cells, which may include adverse actions as well as loss of
symbiotic functions, should be a focus of investigation.
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